AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Schrodinger Inc (NASDAQ:SDGR)
14.93 USD
-0.010 0.067%Sponsored Reports
Loading...
| Previous Close (in USD) | 14.94 |
|---|---|
| Change | -0.010 0.067% |
| 52 W H/L (in USD) | 59.240/20.760 |
| EBITDA (in USD) | -209.152M |
| PE Ratio | -- |
| Volume | 1606494 |
| Diluted Eps TTM | -2.01 |
| Total Assets (in USD) | 802.955M |
|---|---|
| Total Liabilities (in USD) | 254.397M |
| Revenue TTM (in USD) | 188.482M |
| Cash (in USD) | 161.066M |
| Market Cap (in USD) | 1,606.942 M |
| Revenue Per Share TTM | 2.618 |
| Gross Profit TTM (in USD) | 101.022M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Employees: 867
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Ramy Farid Ph.D. | CEO, Pres & Director | 1964 |
| 2. | Dr. Richard A. Friesner Ph.D. | Co-Founder, Scientific Advisory Chairman and Director | 1953 |
| 3. | Mr. Kenneth Patrick Lorton | Exec. VP & CTO | 1984 |
| 4. | Dr. Robert Lorne Abel Ph.D. | Exec. VP, Chief Computational Scientist and Head of Modeling R&D | 1982 |
| 5. | Dr. Karen Akinsanya Ph.D. | Pres of R&D Therapeutics | 1968 |
| 6. | Prof. William Goddard III | Co-Founder & Scientific Advisor | NA |
| 7. | Dr. Geoffrey Craig Porges MBBS | Exec. VP & CFO | NA |
| 8. | Mr. Shane Brauner | Exec. VP & Chief Information Officer | 1978 |
| 9. | Ms. Jaren Irene Madden | Sr. VP of Investor Relations & Corp. Communications | NA |
| 10. | Ms. Yvonne Tran Esq. | Exec. VP, Chief Legal Officer & Sec. | 1971 |
Peers
Sector: Healthcare
Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
VEEV
Veeva Systems Inc Class A |
-4.220 2.307% | 181.49 | 54.610 | 33.223 | 12.830 | 6.727 | 11.138 | 58.844 |
|
MTHRF
M3 Inc |
0.000 0.000% | 11 | 29.720 | 25.000 | 0.046 | 4.379 | 0.041 | 0.118 |
|
MTHRY
M3 Inc |
-0.064 1.341% | 4.75 | 31.840 | 26.247 | 0.047 | 4.597 | 0.041 | 0.118 |
|
BTSG
BrightSpring Health Services, Inc. Common Stock |
+1.540 2.595% | 59.83 | 100.220 | 40.650 | 0.690 | 4.925 | 0.918 | 25.797 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -149.126M | -100.808M | -26.292M | -25.972M | -28.348M |
| Minority Interest | 0.003M | -0.826M | -2.174M | 0.041M | 0.041M |
| Net Income | -149.189M | -101.219M | -26.637M | -25.681M | -28.425M |
| Selling General Administrative | 90.825M | 64.009M | 41.898M | 27.04M | 18.552M |
| Gross Profit | 101.022M | 65.62M | 63.472M | 49.093M | 42.937M |
| Reconciled Depreciation | 4.344M | 2.847M | 3.658M | 3.64M | 2.894M |
| Ebit | -149.123M | -111.443M | -60.916M | -38.715M | -27.157M |
| Ebitda | -144.779M | -119.955M | -85.521M | -44.997M | -24.263M |
| Depreciation And Amortization | 4.344M | -8.512M | -24.605M | -6.282M | 2.894M |
| Operating Income | -149.123M | -111.443M | -60.916M | -38.715M | -27.969M |
| Other Operating Expenses | 327.772M | 249.374M | 169.011M | 124.258M | 94.608M |
| Interest Expense | 0.003M | 22.82M | 65.061M | 23.775M | 0M |
| Tax Provision | 0.063M | 0.411M | 0.345M | -0.291M | 0.077M |
| Interest Income | - | 1.057M | 2.253M | 1.878M | 0.433M |
| Net Interest Income | - | 1.057M | 2.253M | 1.878M | 0.433M |
| Income Tax Expense | 0.063M | 0.411M | 0.345M | -0.291M | 0.077M |
| Total Revenue | 180.955M | 137.931M | 108.095M | 85.543M | 66.639M |
| Total Operating Expenses | 247.839M | 177.063M | 124.388M | 87.808M | 70.906M |
| Cost Of Revenue | 79.933M | 72.311M | 44.623M | 36.45M | 23.702M |
| Total Other Income Expense Net | -0.003M | 10.635M | 34.624M | 12.743M | -0.812M |
| Net Income From Continuing Ops | -149.189M | -101.219M | -26.637M | -25.681M | -28.425M |
| Net Income Applicable To Common Shares | -149.186M | -100.393M | -24.463M | -24.571M | -28.425M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 802.955M | 688.587M | 756.487M | 746.263M | 155.27M |
| Intangible Assets | - | 0.587M | - | - | - |
| Other Current Assets | 9.926M | 26.949M | 16.837M | 8.864M | 6.968M |
| Total Liab | 254.397M | 240.682M | 199.402M | 122.244M | 248.593M |
| Total Stockholder Equity | 548.558M | 447.894M | 557.071M | 624.015M | -93.364M |
| Other Current Liab | 43.759M | 30.392M | 25.722M | 14.861M | 10.858M |
| Common Stock | 0.722M | 0.714M | 0.71M | 0.699M | 0.061M |
| Capital Stock | 0.722M | 0.714M | 0.71M | 0.699M | 0.061M |
| Retained Earnings | -338.418M | -379.138M | -229.952M | -129.559M | -105.096M |
| Good Will | 4.791M | 4.791M | - | - | - |
| Other Assets | - | 3.311M | 2.851M | 2.352M | 2.338M |
| Cash | 161.066M | 90.474M | 120.267M | 202.296M | 25.986M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 133.673M | 108.799M | 91.211M | 73.205M | 45.02M |
| Current Deferred Revenue | 56.231M | 57.931M | 55.368M | 45.403M | 25.054M |
| Net Debt | -33.184M | 26.017M | -40.398M | -190.532M | -11.514M |
| Short Term Debt | 16.868M | 11.006M | 2.042M | 4.543M | 5.584M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 127.882M | 116.491M | 79.869M | 11.764M | 14.472M |
| Other Stockholder Equity | 885.973M | 828.7M | 786.964M | 6.295M | -179.925M |
| Property Plant Equipment | - | 120.226M | 10.025M | 5.14M | 19.03M |
| Total Current Assets | 567.796M | 533.989M | 625.06M | 682.978M | 118.536M |
| Long Term Investments | 83.251M | 25.683M | 43.167M | 45.664M | 15.366M |
| Short Term Investments | 307.688M | 360.613M | 456.212M | 440.395M | 59.844M |
| Net Receivables | 89.116M | 69.09M | 40.551M | 35.378M | 25.738M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -13.137M | -8.807M | -3.955M | - |
| Accounts Payable | 16.815M | 9.47M | 8.079M | 8.398M | 3.524M |
| Accumulated Other Comprehensive Income | 0.281M | -2.382M | -0.651M | 0.317M | 0.016M |
| Non Currrent Assets Other | 6.014M | 3.311M | 2.851M | 2.352M | 2.338M |
| Non Current Assets Total | 235.159M | 154.598M | 131.427M | 63.285M | 36.734M |
| Capital Lease Obligations | 127.882M | 116.491M | 79.869M | 11.764M | 14.472M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 90.023M | -9.645M | -379.183M | -53.855M | 11.194M |
| Total Cashflows From Investing Activities | 90.023M | -16.812M | -381.721M | -53.855M | 11.194M |
| Total Cash From Financing Activities | 2.11M | 7.952M | 541.274M | 28.684M | 80.273M |
| Net Income | -149.189M | -101.219M | -26.637M | -25.681M | -28.425M |
| Change In Cash | -27.55M | -79.529M | 176.31M | -51.23M | 67.756M |
| Begin Period Cash Flow | 123.267M | 202.796M | 26.486M | 77.716M | 9.96M |
| End Period Cash Flow | 95.717M | 123.267M | 202.796M | 26.486M | 77.716M |
| Total Cash From Operating Activities | -119.683M | -70.669M | 16.757M | -26.059M | -23.711M |
| Depreciation | 4.344M | 2.847M | 3.658M | 3.64M | 2.894M |
| Other Cashflows From Investing Activities | - | - | - | -52.019M | 16.453M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 6.437M | 7.336M | 2.912M | -3.859M |
| Sale Purchase Of Stock | - | 7.952M | 215.674M | 30.442M | 80.273M |
| Other Cashflows From Financing Activities | 90.023M | 7.952M | 4.183M | 28.135M | 79.377M |
| Capital Expenditures | 8.014M | 7.167M | 2.538M | 1.836M | 5.259M |
| Change In Working Capital | -21.375M | 4.677M | 59.176M | 4.295M | 0.281M |
| Other Non Cash Items | 6.907M | 0.811M | 2.137M | 1.051M | -0.149M |
| Free Cash Flow | -127.697M | -77.836M | 14.219M | -27.895M | -28.97M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 2 years ago | 3679424 |
| 2. | ARK Genomic Revolution ETF | 2 years ago | 2519472 |
| 3. | ARK Genomic Revolution | 2 years ago | 2494942 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 2006168 |
| 5. | CS (Lux) Digital Health Equity SB USD | 2 years ago | 1900000 |
| 6. | Vanguard Small Cap Index | 2 years ago | 1599196 |
| 7. | iShares Russell 2000 ETF | 2 years ago | 1263108 |
| 8. | Vanguard Small Cap Growth Index Inv | 2 years ago | 903549 |
| 9. | Lazard Global Robotics & Automation | 2 years ago | 903461 |
| 10. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 819393 |
| 11. | Baillie Gifford Global Discovery A Acc | 2 years ago | 727836 |
| 12. | Edinburgh Worldwide Ord | 2 years ago | 707781 |
| 13. | Nikko AM ARK Disruptive Innovation A USD | 2 years ago | 668865 |
| 14. | Stephens SMID Select Growth | 2 years ago | 590665 |
| 15. | Fidelity Small Cap Index | 2 years ago | 558053 |
| 16. | MFS New Discovery I | 2 years ago | 529556 |
| 17. | Nikko AM ARK Pstv Chg Innovt P JPY Acc | 2 years ago | 513754 |
| 18. | Fidelity Select Biotechnology | 2 years ago | 495801 |
| 19. | Old Westbury Small & Mid Cap Strategies | 2 years ago | 491626 |
| 20. | SPDR® Portfolio S&P 600 Sm Cap ETF | 2 years ago | 481941 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 2 years ago | 8763505 |
| 2. | Vanguard Group Inc | 2 years ago | 6809024 |
| 3. | Baillie Gifford & Co Limited. | 2 years ago | 2612007 |
| 4. | ARK Investment Management LLC | 2 years ago | 2517985 |
| 5. | Sumitomo Mitsui Trust Holdings Inc | 2 years ago | 2192972 |
| 6. | State Street Corporation | 2 years ago | 2055344 |
| 7. | Credit Suisse First Boston (CSFB) | 2 years ago | 1988431 |
| 8. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1780197 |
| 9. | Nikko Asset Management Americas Inc | 2 years ago | 1289511 |
| 10. | Lazard Asset Management LLC | 2 years ago | 1234266 |
| 11. | Geode Capital Management, LLC | 2 years ago | 1203585 |
| 12. | Dimensional Fund Advisors, Inc. | 2 years ago | 1048891 |
| 13. | Stephens Inv Mgmt Group LLC | 2 years ago | 992313 |
| 14. | FMR Inc | 2 years ago | 963783 |
| 15. | Goldman Sachs Group Inc | 2 years ago | 821840 |
| 16. | Massachusetts Financial Services Company | 2 years ago | 800529 |
| 17. | Tocqueville Asset Management L.P. | 2 years ago | 663965 |
| 18. | Fred Alger Management, LLC | 2 years ago | 632848 |
| 19. | Northern Trust Corp | 2 years ago | 597732 |
| 20. | Bank of New York Mellon Corp | 2 years ago | 480442 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...